Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

Stopped early · Not applicable

Conditions studied: Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy. It may also help relieve fatigue in patients with anemia. PURPOSE: This randomized clinical trial is studying how well epoetin alfa works in treating patients with anemia who are undergoing chemotherapy for cancer.

Key facts

Study ID

NCT00258440

Run by

OHSU Knight Cancer Institute

People needed

7

Starts

2003-05-01

Expected to finish

2008-09-01

Last updated by the study team

2017-05-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Patient has uncontrolled hypertension
• Patient has history of symptomatic cardiac disease
• Patient has serious intercurrent illness
• The patient is pregnant, has a positive serum HCG or is lactating Patient has known hypersensitivity to mammalian cell-derived products or human albumin.
• Patient has diagnosis of polycythemia vera, chronic myelogenous leukemia, myelodysplastic syndrome
• May not be due for transplant within 24 weeks
• Anemia due to factors other than cancer.
• History of a thrombotic vascular event.
• History of seizures
• Patient has received a red blood cell growth factor (epoetin alfa or darbepoetin) within the last 60 days

Where it is running

• OHSU Knight Cancer Institute — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.